Publication: World policy battles on pharmaceutical patent protection : micro-history of a forum shift and its legal implications
Loading...
Identifiers
Publication date
2013-03
Defense date
Authors
Advisors
Tutors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidad Carlos III de Madrid
Impact
Export
Abstract
La internacionalización de la protección de la propiedad intellectual e industrial fue objeto
en los años 90 de un desplazamiento de foro desde la OMPI a la OMC, bajo la presión de los países
exportadores de tecnología y sus empresas: el producto fue el ADPIC. Este acuerdo fue diseñado para elevar
los estándares de protección empleando una estructura regulatoria basada en meros periodos de transición y
minusvalorando los efectos sociales de la eventual pero previsible falta de capacidad de producción farmacéutica
en muchos países en desarrollo (artículo 31.f). A resultas, los países exportadores e importades de
tecnología están inmersos hoy en día en un proceso de reregulación dirigido a asegurar las “flexibilidades”
inherentes al ADPIC, bajo el estandarte del acceso a medicamentos asequibles en el mundo en desarrollo.
The internationalization of intellectual property protection was subject to a historical forum shift from WIPO to WTO in the 90s under the pressure of technology-exporting countries and their IP constituencies: the TRIPs agreement was its product. However, the agreement was designed to ratchet up global IP standards under a narrow regulatory structure based on mere phase-ins, and without considering social realities such as the eventual lack of pharmaceutical manufacturing capacity in many developing countries (article 31.f). As a result, technology-exporting and technology-importing countries are immersed in a tense ongoing re-regulatory process aiming to secure TRIPS inner "flexibilities", under the banner of access to affordable medicines in the developing world.
The internationalization of intellectual property protection was subject to a historical forum shift from WIPO to WTO in the 90s under the pressure of technology-exporting countries and their IP constituencies: the TRIPs agreement was its product. However, the agreement was designed to ratchet up global IP standards under a narrow regulatory structure based on mere phase-ins, and without considering social realities such as the eventual lack of pharmaceutical manufacturing capacity in many developing countries (article 31.f). As a result, technology-exporting and technology-importing countries are immersed in a tense ongoing re-regulatory process aiming to secure TRIPS inner "flexibilities", under the banner of access to affordable medicines in the developing world.
Description
Keywords
Regulation, Intellectual property, Flexibilities, Pharmaceutical patents, Access to medicines, Generics, Trade, Regulación, Propiedad intelectual, Flexibilidades, Patentes farmaceúticas, Acceso a medicamentos, Genéricos, Comercio
Bibliographic citation
Cuadernos de derecho transnacional, vol. 5, n. 1, marzo 2013, pp. 217-228